Certara (NASDAQ:CERT) Shares Down 4.6% – Here’s What Happened

Certara, Inc. (NASDAQ:CERT) shares traded down 4.6% during mid-day trading on Thursday . The stock traded as low as $10.39 and last traded at $10.42. 216,356 shares were traded during trading, a decline of 74% from the average session volume of 838,846 shares. The stock had previously closed at $10.92.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on CERT shares. Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, November 7th. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday, September 27th. Finally, Robert W. Baird lowered their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $15.92.

Certara Stock Performance

The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -53.00, a price-to-earnings-growth ratio of 5.86 and a beta of 1.53. The firm’s 50 day moving average is $10.85 and its 200-day moving average is $12.52.

Certara (NASDAQ:CERT) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million during the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. The company’s revenue was up 10.7% on a year-over-year basis. Sell-side analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.39% of the stock is owned by insiders.

Institutional Investors Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of the business. Blue Trust Inc. acquired a new position in Certara in the second quarter worth about $26,000. Innealta Capital LLC acquired a new position in shares of Certara in the 2nd quarter worth approximately $36,000. KBC Group NV lifted its position in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after buying an additional 1,584 shares during the period. Intech Investment Management LLC acquired a new stake in Certara in the 2nd quarter valued at $152,000. Finally, Algert Global LLC bought a new stake in Certara in the second quarter valued at $156,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.